Table 2

Success states by pillar identified by Global Advisory Committee members in phase II

Drug developmentClinical careAccess to care
Improved trial design across age groupsBiomarkers to support timely and accurate diagnosisAccess to high quality, specialised care regardless of location
Improved outcome measures to be uniformly implemented across sponsorsImproved support programmes to encourage treatment adherence among patientsImproved access to care for individuals of lower socioeconomic status
Improved biomarkers to better define heterogeneity and predict response to investigational therapiesBiomarkers to predict patients’ responses to therapies to support design of treatment regimensImproved global access to advanced diagnostics and therapies